The global 3D bioprinting in medical market was valued at $1.1 billion in 2022, and is projected to reach $4.9 billion by 2032, growing at a CAGR of 15.5% from 2023 to 2032.
3D bioprinting is an advanced technology that involves the deposition of living cells, biomaterials, and other bioactive substances to create three-dimensional structures that mimic the architecture and function of natural tissues and organs. This innovative approach allows for the precise fabrication of complex biological constructs, enabling applications in regenerative medicine, drug testing, and the potential development of functional tissues or organs for transplantation. The process utilizes computer-aided design (CAD) to guide the deposition of bioink, composed of cells and supportive materials, to construct intricate and customized biological structures.
The 3D bioprinting market is driven by a combination of technological advancements, increasing applications in healthcare and research, rising demand for personalized medicine, and supportive regulatory initiatives. The growing incidence of chronic diseases worldwide, such as heart disease, diabetes, and organ failure, is a significant driver. 3D bioprinting provides a promising avenue for developing replacement tissues and organs for patients suffering from these conditions, thereby driving the market forward. The increase in demand for personalized medicine, which tailors medical treatment to individual patients, fuels the adoption of 3D bioprinting. The ability to create tissues and organs specific to a patient's unique anatomy reduces the risk of rejection and enhances the overall success of transplants, addressing a critical need in healthcare and thereby supporting market growth.
However, high costs of bioprinters, lack of structured regulatory frameworks related to approvals for 3D bioprinters, copyright & patent infringement concerns, biocompatibility issues of 3D-bioprinted medical devices, and lack of technical expertise are the major factors hampering the growth of the market. Conversely, untapped markets in the developing countries are expected to provide lucrative opportunities for the market players.
The 3D bioprinting in medical market is segmented into products & solutions, technology, application, end user, and region. By products & solutions, the market is classified into bioprinters, consumables & accessories, and software & services. By technology, the market is classified into extrusion-based bioprinting, inkjet based bioprinting, laser assisted bioprinting, and others. By application, the market is segregated into tissue engineering & regenerative medicine, drug discovery & development, and others. By end user, the market is classified into biotechnology & pharmaceutical companies, academic & research institutes, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global 3D bioprinting in medical market are Organovo Holdings, Inc., Cyfuse Biomedical K.K., BICO, REGEMAT 3D, Desktop Metal, Inc., Medprin, Shining 3D, CollPlant Biotechnologies Ltd, Advanced Solutions, Inc., and 3D Systems Corporation. Key players operating in the market have adopted product launch, partnership, agreement, acquisition, collaboration, expansion, and product upgrade as their key strategies to expand their product portfolio.
3D bioprinting is an advanced technology that involves the deposition of living cells, biomaterials, and other bioactive substances to create three-dimensional structures that mimic the architecture and function of natural tissues and organs. This innovative approach allows for the precise fabrication of complex biological constructs, enabling applications in regenerative medicine, drug testing, and the potential development of functional tissues or organs for transplantation. The process utilizes computer-aided design (CAD) to guide the deposition of bioink, composed of cells and supportive materials, to construct intricate and customized biological structures.
The 3D bioprinting market is driven by a combination of technological advancements, increasing applications in healthcare and research, rising demand for personalized medicine, and supportive regulatory initiatives. The growing incidence of chronic diseases worldwide, such as heart disease, diabetes, and organ failure, is a significant driver. 3D bioprinting provides a promising avenue for developing replacement tissues and organs for patients suffering from these conditions, thereby driving the market forward. The increase in demand for personalized medicine, which tailors medical treatment to individual patients, fuels the adoption of 3D bioprinting. The ability to create tissues and organs specific to a patient's unique anatomy reduces the risk of rejection and enhances the overall success of transplants, addressing a critical need in healthcare and thereby supporting market growth.
However, high costs of bioprinters, lack of structured regulatory frameworks related to approvals for 3D bioprinters, copyright & patent infringement concerns, biocompatibility issues of 3D-bioprinted medical devices, and lack of technical expertise are the major factors hampering the growth of the market. Conversely, untapped markets in the developing countries are expected to provide lucrative opportunities for the market players.
The 3D bioprinting in medical market is segmented into products & solutions, technology, application, end user, and region. By products & solutions, the market is classified into bioprinters, consumables & accessories, and software & services. By technology, the market is classified into extrusion-based bioprinting, inkjet based bioprinting, laser assisted bioprinting, and others. By application, the market is segregated into tissue engineering & regenerative medicine, drug discovery & development, and others. By end user, the market is classified into biotechnology & pharmaceutical companies, academic & research institutes, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global 3D bioprinting in medical market are Organovo Holdings, Inc., Cyfuse Biomedical K.K., BICO, REGEMAT 3D, Desktop Metal, Inc., Medprin, Shining 3D, CollPlant Biotechnologies Ltd, Advanced Solutions, Inc., and 3D Systems Corporation. Key players operating in the market have adopted product launch, partnership, agreement, acquisition, collaboration, expansion, and product upgrade as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the 3d bioprinting in medical market analysis from 2022 to 2032 to identify the prevailing 3d bioprinting in medical market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the 3d bioprinting in medical market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global 3d bioprinting in medical market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By End users
- Biotechnology and pharmaceutical companies
- Academic and research institutes
- Others
By Products and solutions
- Bioprinters
- Consumables and accessories
- Software and services
By Technology
- Extrusion based bioprinting
- Inkjet based bioprinting
- Laser assisted bioprinting
- Others
By Application
- Tissue engineering and regenerative medicine
- Drug discovery and development
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa,
- Saudi Arabia
- Rest of LAMEA
- Cyfuse Biomedical K.K.
- BICO
- Desktop Metal, Inc.
- Medprin
- CollPlant Biotechnologies Ltd
- 3D Systems Corporation
- Organovo Holdings, Inc.
- REGEMAT 3D
- Shining 3D
- Advanced Solutions, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: 3D BIOPRINTING IN MEDICAL MARKET, BY PRODUCTS AND SOLUTIONS
CHAPTER 5: 3D BIOPRINTING IN MEDICAL MARKET, BY TECHNOLOGY
CHAPTER 6: 3D BIOPRINTING IN MEDICAL MARKET, BY APPLICATION
CHAPTER 7: 3D BIOPRINTING IN MEDICAL MARKET, BY END USERS
CHAPTER 8: 3D BIOPRINTING IN MEDICAL MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Cyfuse Biomedical K.K.
- BICO
- Desktop Metal, Inc.
- Medprin
- CollPlant Biotechnologies Ltd
- 3D Systems Corporation
- Organovo Holdings, Inc.
- REGEMAT 3D
- Shining 3D
- Advanced Solutions, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 316 |
| Published | December 2023 |
| Forecast Period | 2022 - 2032 |
| Estimated Market Value ( USD | $ 1.1 billion |
| Forecasted Market Value ( USD | $ 4.9 billion |
| Compound Annual Growth Rate | 16.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
